Tetra Radar · FDA Approvals · Decision date

MK-8591A: FDA decision date

Merck & Co. Inc (MRK) · 28 April 2026

The FDA set a PDUFA, or target action, date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials.

Source: 10-K of 24 February 2026

The FDA approved it on 20 April 2026.

The FDA approved IDVYNSO to treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.

Merck & Co. Inc on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.